Milan, Italy

Alberto Gasco

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Location History:

  • Rozzano, IT (2013)
  • Milan, IT (2015)

Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Alberto Gasco: Innovator in Antitumor Compounds

Introduction

Alberto Gasco is a notable inventor based in Milan, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds with antitumor activity. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.

Latest Patents

Gasco's latest patents include "Water soluble furoxan derivatives having antitumor activity." This invention provides water-soluble compounds with a furoxan structure that can inhibit metabolic pathways involved in tumor development. The compounds are also described for their use as medicaments in tumor therapy and as adjuvants in immunotherapy protocols against neoplasms. Another significant patent is "Nitric oxide furoxan derivative compounds endowed with antitumoral activity." This invention relates to nitric oxide furoxan derivative compounds that have shown effectiveness in treating tumors and may serve as adjuvants in cancer immunotherapy.

Career Highlights

Throughout his career, Gasco has worked with esteemed organizations such as Humanitas Mirasole S.p.a. and Istituto Oncologico Veneto Irccs. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.

Collaborations

Gasco has collaborated with notable colleagues, including Antonella Viola and Enzo Bronte. These partnerships have further enriched his research and development efforts in the field of oncology.

Conclusion

Alberto Gasco's contributions to the field of antitumor compounds highlight his dedication to advancing cancer treatment. His innovative patents and collaborations reflect his commitment to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…